

Figure 1: Methyl (E)-(6-12-14-(4-fluoronheayl)-6-isopropyl-2-[snethyl(methylsulfonyl)amino]pyrimidin-6-yllyinyl]-(4R,6S)-2,2-dimethyl[1,3]dioxan-4-ylacotate




2-theta	d-spacing	Relative Intensities
5.7	15.4	51
8.7	10.1	25
9.5	9.3	100
13.6	6.5	54
17.5	5.1	58
19.0	4.7	41
19.9	4.5	53
20.8	4.3	29
21,8	4.1	34
22,4	4.0	41

Figure 2: Ethyl (E)-(6-[2-14-(4-fluorophenyl)-6-isopropyl-2-imethyl(methylsulfonyl)amino]pyrimidin-5-yllyinyl\4R.6S)-2,2-dimethyl[1,3]dioxan-4-yllactate




2-theta	d-spacing	Relative Intensities
5.9	15.0	23
8.0	11.0	33
12.2	7.3	21
15.9	5.6	100
18.4	4.8	65
19.5	4.6	82
19.7	4.5	45
23.0	3.9	53
24.3	3.7	37
25.0	3.6	29

Figure 3: iso-Propyl (E) (6-(2-(4-(4-flaorophenyl)-6-isopropyl-2imethyl(methylsufionyl)aminolpyrimidin-5-yl)vinyl)(4R,6S)-2,2-dimethyl[1,3]dioxan-4-ylacetate




2-theta	d-spacing	Relative Intensities
6.0	14.7	35
7.0	12.6	41
7,8	11.3	90
8.7	10.1	37
10.4	8.5	27
11.6	7.6	100
13,0	6.8	20
14.7	6.0	19
15.5	5.7	56
20.2	4.4	53

Figure 4: a-hexvi (E)-(6-[2-[4-[4-fluoropheny])-6-isopropy]-2-[methyl[methylsulfanyl]amino[pyrimidin-5-vilvinyl](4R,6S)-2,2-dimethyl[1,3]dioxan-




2-theta	d-spacing	Relative Intensities
5.3	16.8	18
7.1	12,4	100
11.4	7.8	10
14.2	6.2	19
14.8	6.0	14
18.9	5.7	27
20.1	4.4	10
20.4	4.4	\$
21.4	4.1	12

Figure 5: Ethyl-(E)-7-[4-(4-finorophenyl)-5-isepropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yll(3R,5S)-3,5-dihydroxyhsut-6-enoste




2-theta	d-spacing	Relative Intensities
4.3	20.4	13
8.1	11.0	100
11,3	7.8	48
12.4	7.1	21
15.1	5.9	18
19.9	4.5	56
21.0	4.2	41
21.7	4.1	18
22.1	4.0	26
23.5	3.8	15

Figure 6: iso-Propvi-(E:-7-14-(4-finorophenyi)-5-sopropvi-2-[methyl/methylsulfonyi)aminolpyrimidin-5-yil(3E.57)-3.5-dihydroxyhspi-6-spoate




2-theta	d-spacing	Relative Intensities
9.8	9,0	88
12.2	7.3	2,4
13.6	6.5	20
17.3	5.1	57
18.5	4.8	18
19.6	4.5	24
20.1	4,4	53
21.1	4,2	100
22.4	4.0	20
23.3	3.8	16

Figure 7: tert-Butyl-(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsu)fonyl)amino]pyrimidin-5-yll(3R,5S)-3,5-dihydroxyhept-6-enosto



2-thets	d-spacing	Relative Intensities
9.8	9.1	31
17.2	5.2	13
18.2	4.9	35
19,4	4.6	15
19.9	4.5	50
20.6	4.3	33
20.8	4.3	100
22.1	4.0	12
25.1	3.5	10
26.3	3.4	18

Figure 3: (E)-7-[4-(4-finoronheavi)-6-isopropyl-2: [methyl(methylsnKonyi)amino]pyrimidin-5-yll(3R.55)-3.5-dihydroxyhept-6-enoic acid/3.6-lactone



2-thets	d-spacing	Relative Intensities
7.9	11.1	76
11,9	7.4	25
15.9	5.6	69
20.3	4.4	100
21.7	4.1	59
22.5	3.9	31